Letters

Concerning the article by Rex Dalton “Should Reviewers Sign Their Critiques?” (The Scientist, July 11, page 5), my answer to the question would be emphatically “yes!” The arguments against it are unrealistic. Reviewers should have accountability. I have a modest proposal an Author’s Bill of Rights, which follows: 1. The reviewer should have credentials of scholarship equal to those required of the author. (Passing the paper to the postdoc down the hall from th

Written byLewis Mokrasch
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Concerning the article by Rex Dalton “Should Reviewers Sign Their Critiques?” (The Scientist, July 11, page 5), my answer to the question would be emphatically “yes!” The arguments against it are unrealistic. Reviewers should have accountability. I have a modest proposal an Author’s Bill of Rights, which follows:

1. The reviewer should have credentials of scholarship equal to those required of the author. (Passing the paper to the postdoc down the hall from the editor is not satisfactory) If the name of the reviewer will not be given, then let his rank and experience be stated.

2. The author should have the right to suggest alternate reviewers.

3. If a review is negative, the reasons for the criticism should be fully documented.

4. If changes are recommended in a paper, the reasons for such changes should also be fully documented.

5. The tenor of the review should be consistent with ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies